Register
Community
Overview
Experts
Editors
Fellows
Code of conduct
Company
About Us
FAQs
Privacy Policy
Terms of Use
Careers
Programs
News
News Releases
Press Coverage
Publications
Blog
Contact Us
Sign in
Please select the option that best describes you:
Topics:
Breast Cancer
•
Gynecologic Cancers
•
Medical Oncology
•
Survivorship
•
Genetics
•
Breast Cancer, Non-metastatic
•
Sexual Health
Would you consider HRT after risk-reducing salpingo-oophorectomy for a young (mid-30s) patient with BRCA1 and a history of TNBC?
Related Questions
In which scenarios do you use vaginal estrogen in patients with history of HR positive breast cancer?
Would you provide anthracycline-based therapy for early stage node negative triple-negative breast cancer in patient with echocardiogram showing grade 1 diastolic dysfunction?
Would history of breast cancer deter you from using ospemifene for severe vaginal dryness/dyspareunia?
Do you consider post-NAC isolated tumor cells in LNs to be residual disease in TNBC to justify capecitabine?
In a patient with early stage HER2+ breast cancer s/p surgery, would you consider a noncytotoxic chemotherapy approach with anti-Her2 therapy alone if the PS is borderline and/or patient declines chemotherapy?
Do you have concerns about the generalizability of Oncotype testing/Mammaprint testing in making chemotherapy decisions for non-Caucasian women?
How would you decide the duration of ovarian suppression in premenopausal females with early stage ER+ breast cancer?
How do you approach treatment for a patient with T2N0, ER+/PR+, HER2 negative breast cancer with planned TC treatment following a hypersensitivity reaction?
What is your treatment approach in a patient with cT2 ER+HER2+ breast cancer who refuses neoadjuvant chemotherapy?
Does the degree of hormone receptor positivity influence your decision to perform Oncotype testing?
